Resting and Dynamic Brain Glutamate by MRS In Vivo: Relation to Suicidal Behavior
A Neuroimaging Study on Brain Chemistry in Depressed and Healthy Individuals
Sponsor: National Institutes of Health
Enrolling: Male and Female Patients
Study Length: 3 Weeks
Clinic Visits: 4
IRB Number: AAAV4037
Contact: Camila Gomez Restrepo: / cr3438@tc.columbia.edu
Additional Study Information: Rising suicide rates in the US underscore the need to identify new and effective medications for depression and suicide risk. Evidence suggests that certain brain chemicals such as glutamate play an important role in depression and suicide. This project will assess differences in brain glutamate both at rest and during task-related activity in depressed individuals with and without prior suicidal behavior, compared with healthy individuals.
This study is closed
Investigator
Sarah Herzog, PhD
Do You Qualify?
Have you had ketamine in any form in the last 3 months? Yes No
Are you currently pregnant, breastfeeding, or trying to become pregnant? Yes No
Do you have a parent, child, or sibling with a history of schizophrenia? Yes No
Do you have conditions requiring daily use of stimulants, anxiety or sleep medications, antihistamines, or NSAIDs? Yes No
Do you suffer from a psychiatric disorder? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Camila Gomez Restrepo
cr3438@tc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE